NEW YORK, March 5, 2014 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Today, Analysts Review released its analysts' notes regarding Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), Horizon Pharma, Inc. (NASDAQ: HZNP), Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA), and PTC Therapeutics, Inc. (NASDAQ: PTCT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Arena Pharmaceuticals, Inc. Analyst Notes
On February 27, 2014, Arena Pharmaceuticals, Inc. (Arena) reported its financial results for Q4 2013 and full year 2013. Arena's total revenues during the quarter stood at $6.5 million, representing a three-fold growth over revenues of $1.9 million in Q4 2012. Full-year 2013 revenues also registered sharp growth at $81.4 million, compared to $27.6 million in full year 2012. During the quarter, the Company's net loss allocable to common stockholders widened to $23.5 million, or $0.11 per diluted share, from net loss allocable to common stockholders of $21.3 million or $0.10 per diluted share, in Q4 2012. For full year 2013, the net loss narrowed down to $19.4 million, or $0.09 per diluted share, from $88.3 million, or $0.45 per diluted share, in full year 2012. Commenting on the performance, Jack Lief, Arena's President and CEO, stated, "The 2013 US commercial launch of BELVIQ, global expansion of our collaboration with Eisai, and the advancement of our research and development programs have positioned Arena for an outstanding year in 2014." The full analyst notes on Arena Pharmaceuticals, Inc. are available to download free of charge at:
Horizon Pharma, Inc. Analyst Notes
On February 27, 2014, Horizon Pharma, Inc. (Horizon Pharma) announced that it will release its Q4 2013 and full-year 2013 financial results on Thursday, March 13, 2014, followed by a live conference call at 8:00 a.m. ET on the same day to discuss these results. The Company informed that the live webcast, as well as a replay of the same, will be accessible through its Investor Relations website. The full analyst notes on Horizon Pharma, Inc. are available to download free of charge at:
Enanta Pharmaceuticals, Inc. Analyst Notes
On March 3, 2014, Enanta Pharmaceuticals, Inc. (Enanta) announced that it has presented detailed results from the PEARL-III study during the 21st Conference on Retroviruses and Opportunistic Infections (CROI) press conference, and will also present the same as a late-breaker at the conference on March 4, 2014. According to Enanta, the PEARL-III study met its primary and secondary endpoints; sustained virologic response rates 12 weeks post-treatment (SVR12) of 99.5% and 99.0% were achieved with the three-direct-acting antiviral regimen with and without RBV, respectively. The Company noted that there were no study drug discontinuations due to adverse events in the 419-patient study. The full analyst notes on Enanta Pharmaceuticals, Inc. are available to download free of charge at:
Vanda Pharmaceuticals, Inc. Analyst Notes
On February 28, 2014, Vanda Pharmaceuticals, Inc. (Vanda) announced that it has partnered with Erik Weihenmayer, a world-renowned adventurer and the only blind person to climb Mount Everest, to support the Non-24 Share More Campaign and launch the expert podcast series available at Non-24.com. Vanda stated that this national education initiative aims to raise awareness for Non-24-Hour Sleep-Wake Disorder (Non-24), a serious, chronic circadian rhythm disorder that affects up to 70% of people who are totally blind. Commenting on the initiative, Dr. Michael Thorpy, said, "It is common for people who are totally blind to experience symptoms of nighttime sleeplessness and daytime sleepiness, which can impact productivity at work, personal relationships and overall functionality." Thorpy concluded, "Our goal is to create a dialogue about Non-24 in the patient and physician communities given the frequency of misdiagnosis." The full analyst notes on Vanda Pharmaceuticals, Inc. are available to download free of charge at:
PTC Therapeutics, Inc. Analyst Notes
On February 25, 2014, PTC Therapeutics, Inc. (PTC) announced the appointment of Guido Schopen, M.D., as General Manager and Head of Medical Affairs for Europe. PTC informed that Dr. Schopen will be responsible for European commercial operations, reporting to Mark Rothera, Chief Commercial Officer of PTC. According to PTC, Dr. Schopen has more than 20 years of experience in the industry and was most recently the Vice President, Global Commercial Operations and Medical Affairs for TiGenix NV. Commenting on the appointment, Rothera said, "PTC is expanding its commercial footprint with a near term focus on certain pre-approval activities. Our ultimate goal is to build a specialty global commercial organization to bring ataluren to Duchenne muscular dystrophy and cystic fibrosis patients as soon as possible following regulatory approvals. Dr. Schopen's medical and commercial expertise will be instrumental in achieving this goal." The full analyst notes on PTC Therapeutics, Inc. are available to download free of charge at:
About Analysts Review
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review